C3 and Lymphadenopathy: Our previous study found that liproxstatin-1 treatment in MRL/lpr mice significantly mitigated disease progression by inhibition of ferroptosis, reduced the production of autoantibodies, enhanced serum complement component 3, and decreased lymphadenopathy, splenomegaly, and lupus nephritis severity [16].